Research and product development for Crimean-Congo haemorrhagic fever: priorities for 2024-30

Basit Öğe Kaydı
dc.authoridFay, Petra C./0000-0001-5808-4284
dc.authoridKorukluoglu, Gulay/0000-0001-7625-6350
dc.authoridvatansever, zati/0000-0003-3460-3849
dc.contributor.authorSemper, Amanda E.
dc.contributor.authorOlver, Janie
dc.contributor.authorWarner, Jenny
dc.contributor.authorCehovin, Ana
dc.contributor.authorFay, Petra C.
dc.contributor.authorHart, Peter J.
dc.contributor.authorGolding, Josephine P.
dc.date.accessioned2025-05-04T16:47:37Z
dc.date.available2025-05-04T16:47:37Z
dc.date.issued2025
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractCrimean-Congo haemorrhagic fever (CCHF) is a widely distributed and potentially fatal tick-borne viral disease with no licensed specific treatments or vaccines. In 2019, WHO published an advanced draft of a research and development roadmap for CCHF that prioritised the development and deployment of the medical countermeasures most needed by CCHF-affected countries. This Personal View presents updated CCHF research and development priorities and is the product of broad consultation with a working group of 20 leading experts in 2023-24. The strategic goals, milestones, and timelines have been revised and expanded to reflect scientific advances since 2019, including the identification of antibodies with therapeutic potential and the progression of four vaccine candidates through phase 1 clinical trials. This update emphasises the need for a One Health approach to manage CCHF, from integrated crosssectoral surveillance to novel interventions that target ticks and their vertebrate hosts to reduce CCHF virus transmission to humans. The overarching vision for rapid diagnostics and specific therapeutics by 2028, followed by options to limit CCHF virus transmission and control disease by 2030, is deliberately ambitious and will only be achieved through coordinated international action from affected countries, funders, scientists, product developers, manufacturers, regulators, national authorities, and policy makers.
dc.identifier.endpagee234
dc.identifier.issn1473-3099
dc.identifier.issn1474-4457
dc.identifier.issue4
dc.identifier.pmid39522529
dc.identifier.scopusqualityQ1
dc.identifier.startpagee223
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35690
dc.identifier.volume25
dc.identifier.wosWOS:001469990200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofLancet Infectious Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250504
dc.subjectViral Load
dc.subjectVirus
dc.subjectTicks
dc.subjectTransmission
dc.subjectPathogenesis
dc.subjectMaintenance
dc.titleResearch and product development for Crimean-Congo haemorrhagic fever: priorities for 2024-30
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu